Metabolic Syndrome

Chronic Fatigue Syndrome

Premature Aging

RiaGev

Prism Research, Inc.

The Safety and Efficacy Study of RiaGev in Healthy Adults

A Randomized, Double-blind, Comparator-controlled, Cross-over Study to Investigate the Safety and Efficacy of RiaGev™ in Healthy Adults

The change in whole blood NAD+ levels from baseline to day 8 when supplemented with RiaGev™ or comparator. The parameter is measured at Day 1, Day 3, Day 5, and Day 8.

The change in serum glucose as assessed by an Oral Glucose Tolerance Test (OGTT) at t=0, 15m, 30, 45m, 60m, 90m and 2h after a 7-day supplementation with either RiaGev™ or comparator. The measure will take place on Day 1 and Day 8

The change in serum insulin as assessed by an Oral Glucose Tolerance Test (OGTT) at t=0, 15m, 30, 45m, 60m, 90m and 2h after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1 and Day 8.

The change in serum Glutathione/Glutathione disulfide (GSH/GSSG) ratio after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1 and Day 8, before and after exercise.

The change in serum adenosine triphosphate/ adenosine monophosphate (ATP/AMP) ratio after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1, Day 3, Day 5, and Day 8.

The change in salivary cortisol after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1, 3, 5, and 8.

The change in Checklist Individual Strength (CIS) Questionnaire outcome after a 7-day supplementation with either RiaGev™ or comparator. There are twenty question categorized into four categories, including fatigue, concentration, motivation, and physical activity. The total as well as category score will be reported.

Incidence of pre-emergent and post-emergent adverse events when supplemented

Clinical chemistry parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, creatinine, electrolytes (Na, K, Cl), fasting glucose, and estimated glomerular filtration rate (eGFR). The number of out of norm incidence will be reported.

Hematology parameters including white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), red blood cell (RBC) count, hemoglobin, hematocrit, platelet count, RBC indices (mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), The number of out of norm incidence will be reported

Vital signs including blood pressure (BP) and heart rate (HR) are going to be measured. Out of norm incidence will be reported.

Bioenergy Life Science, Inc.

KGK Science Inc.

University of Washington

randomized, double-blind, comparator-controlled, cross-over

G6PD Deficiency

Stroke

This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.

Aspirin

This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.

Clopidogrel

The First Affiliated Hospital of Guangdong Pharmaceutical University

The First Affiliated Hospital of Sun Yat-Sen University

The First Affiliated Hospital of Jinan University

Jieyang Municipal People's Hospital

Meizhou City People's Hospital

Yue Bei People's Hospital

Yunfu People's Hospital

The Forth Affiliated Hospital of Guangxi Medical Hospital

The First Affiliated Hospital of Guangxi Medical Hospital

The Second Affiliated Hospital of Hainan Medical University

Ganzhou Municipal Hospital

The Forth Affiliated Hospital of Nanchang University

Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

A Randomized, Double-blind, Active-Controlled Trial Comparing the Safety and Efficacy of Aspirin Versus Clopidogrel in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency

Protocol-defined hemolysis is defined as one or more of the following conditions: a) Hemoglobin level declined ≥2.5 g/dL from baseline, meanwhile ruling out bleeding events. b) Hemoglobin level declined ≥25% from baseline, meanwhile ruling out bleeding events. c) Clinically relevant hemolytic events, could manifested as fatigue, back pain, anemia, dark urine and jaundice, adjudicated by the adjudication committee ultimately.

Modified Rankin Scale score ranges from 0 to 6, and lower score means more functional independence.

Barthel Index ranges from 0 to 100, and higher score means more functional independence.

National Institutes of Health Stroke Scale ranges from 0 to 42, and higher scores indicate more severe neurologic deficits.

EuroQoL-5 Dimensions questionnaire contains utility index score and visual analogue scale. Utility index score ranges from 0 to 1, and visual analogue scale ranges from 0 to 100. Higher scores indicate more healthy quality of life.

glucose 6 phosphate dehydrogenase/väsimus

The Safety and Efficacy Study of RiaGev in Healthy Adults

Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus